KR20250154513A - 췌장암 치료용 약물 조합 - Google Patents

췌장암 치료용 약물 조합

Info

Publication number
KR20250154513A
KR20250154513A KR1020257033209A KR20257033209A KR20250154513A KR 20250154513 A KR20250154513 A KR 20250154513A KR 1020257033209 A KR1020257033209 A KR 1020257033209A KR 20257033209 A KR20257033209 A KR 20257033209A KR 20250154513 A KR20250154513 A KR 20250154513A
Authority
KR
South Korea
Prior art keywords
cancer
minelide
therapy
paclitaxel
nab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257033209A
Other languages
English (en)
Korean (ko)
Inventor
모하나 알. 벨라가푸디
아쇼크 쿠마르 살루자
Original Assignee
미네암리타 테라퓨틱스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미네암리타 테라퓨틱스, 엘엘씨 filed Critical 미네암리타 테라퓨틱스, 엘엘씨
Publication of KR20250154513A publication Critical patent/KR20250154513A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020257033209A 2023-03-09 2023-03-21 췌장암 치료용 약물 조합 Pending KR20250154513A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363489221P 2023-03-09 2023-03-09
US63/489,221 2023-03-09
PCT/US2023/015813 WO2024186320A1 (en) 2023-03-09 2023-03-21 Drug combination for treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
KR20250154513A true KR20250154513A (ko) 2025-10-28

Family

ID=92675407

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257033209A Pending KR20250154513A (ko) 2023-03-09 2023-03-21 췌장암 치료용 약물 조합

Country Status (5)

Country Link
EP (1) EP4676463A1 (enExample)
JP (1) JP2026507878A (enExample)
KR (1) KR20250154513A (enExample)
AU (1) AU2023435819A1 (enExample)
WO (1) WO2024186320A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596977B (zh) 2009-05-07 2016-06-29 明尼苏达大学评议会 雷公藤内酯前药
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
WO2014167581A2 (en) * 2013-04-01 2014-10-16 Laurus Labs Private Limited An improved process for the preparation of triptolide prodrugs
WO2015127011A1 (en) * 2014-02-21 2015-08-27 Institute Of Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center C-myc as a biomarker for tumor sensitivity to treatment with rna polymerase ii inhibition
US10975146B2 (en) * 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
US11819498B2 (en) * 2019-12-30 2023-11-21 Unm Rainforest Innovations Methods and compositions for treating autophagy related disease states and conditions utilizing AMPK activation
WO2021231678A1 (en) * 2020-05-13 2021-11-18 University Of Massachusetts Reducing prominin2-mediated resistance to ferroptotic cell death

Also Published As

Publication number Publication date
AU2023435819A1 (en) 2025-10-02
JP2026507878A (ja) 2026-03-06
EP4676463A1 (en) 2026-01-14
WO2024186320A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
RU2577278C2 (ru) Способы комбинированной терапии для лечения пролиферативных заболеваний
CN1151118A (zh) 癌症的治疗与预防转移
JP2017521499A (ja) 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
Abou-Jawde et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial
KR20160021084A (ko) 사람에서 고형 종양의 치료를 위한 씨. 노비
CN106237340A (zh) 透明质酸纳米颗粒在制备治疗淋巴系统肿瘤的药物的用途
JP2019505586A (ja) 神経芽細胞腫及びその他のがん治療のための治療ナノ粒子
CN110292578A (zh) 阿帕替尼在制备治疗急性髓系白血病的药物中的新应用
CN115429883A (zh) 用于联合治疗的抗肿瘤药物组合物
CA2912830A1 (en) Specific cancer treatment regimens with ganetespib
JP2025509278A (ja) 小細胞肺癌を治療する方法
JP2026507878A (ja) 膵臓癌の処置のための複合薬
RU2678103C2 (ru) Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта
US20250339452A1 (en) Drug combination for treatment of gastric cancer
US20210386736A1 (en) Combination therapy for treating cancer
CN105435216B (zh) 重组人钙调磷酸酶b亚基的应用
CN111840541A (zh) 聚肌苷酸胞苷酸联合抗cd47抗体在肿瘤治疗中的应用
US20260048111A1 (en) Pharmaceutical Composition, Preparation Method and Use Thereof
JP2026009993A (ja) 胃癌の治療のための薬物の組み合わせ
Xiang¹ et al. Advancing immune checkpoint
WO2026107242A1 (en) Ras and pd-1 or pd-l1 inhibitors combination therapy
CN110215511A (zh) 微肽asrps在治疗癌症中的应用
CN121489929A (zh) 卞硒腈在制备预防和/或治疗胰腺癌药物中的应用
WO2025250689A1 (en) Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics
CN105534972A (zh) 一种治疗乳腺癌的药物组合物及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000